

## Particulate Matter and the Environmental Protection Agency Setting the Right Standard

Air quality standards, such as the particulate matter (PM) air pollution standards currently under review by the Environmental Protection Agency (EPA), have a critical role in improving public health in the United States. Yet the setting of these standards has proven to be fertile ground for contentious and partisan debate that often ignores the scientific and health protective basis for the standard that is mandated by the Clean Air Act. PM air pollution is pervasive in the United States, and a more protective PM National Ambient Air Quality Standard (NAAQS) would provide significant public health and economic benefits. As a result, the PM NAAQS is of great interest to stakeholders including affected industries, environmental groups, state and local governments, and professional health organizations like the American Thoracic Society. Unfortunately, this critical PM air quality standard review is occurring at a time when the Clean Air Act and the EPA are under attack in Congress. There is now serious concern that the setting of the most health-appropriate PM air quality standard may again be jeopardized due to this political discord.

The Clean Air Act passed by Congress in the 1970s requires that the EPA promulgate a NAAQS that is evidence based and that protects the public health with “an adequate margin of safety,” regardless of cost. PM has been causally linked by independent researchers to a broad range of adverse health effects, including both respiratory and cardiovascular illness and death (1–4). Indeed, scientists at the U.S. EPA have recently estimated that, each year, almost one in five ischemic heart deaths in the United States is linked to the public’s exposure to PM<sub>2.5</sub> (PM with a mass median aerodynamic diameter < 2.5 μm) (5). Other investigators have documented that as PM pollution levels have been reduced in U.S. cities, risk of death has decreased (6, 7). As a result, the EPA has estimated that roughly 90% of the dollar valuation of the health benefits achieved by implementing the Clean Air Act through 2010 has been due to reductions in PM air pollution (8). In addition, PM air pollution has been shown to be a major contributor to respiratory illness, including asthma ER visits and reductions in children’s lung function (4, 9), especially worrisome findings with potential long-term health implications to a wide number of Americans. Thus, the evidence indicates that PM is one of the most critical air pollutants to control if we are to achieve better public health through cleaner air.

But the past as prologue is not reassuring with regard to the setting of an appropriately protective air quality standard for PM. The last review was quite contentious, and not nearly enough progress was achieved. While the short-term (24-h peak) NAAQS was made more protective, the long-term NAAQS was left alone, in conflict with the advice of the EPA’s independent Clean Air Scientific Advisory Committee (CASAC).

Based on past and new studies, the CASAC stated, in a September 10, 2010 letter to the EPA Administrator, that the committee “supports the EPA staff’s conclusion... that currently

available information clearly calls into question the adequacy of the current standards.” The committee also concurred with EPA staff that consideration be given to both an alternative annual standard for PM<sub>2.5</sub> in the range of 13 to 11 μg/m<sup>3</sup>, as well as an alternative short-term (24-h) PM<sub>2.5</sub> standard level of 30 μg/m<sup>3</sup> (particularly in conjunction with an annual standard level of 11 μg/m<sup>3</sup>).

We agree with CASAC that the present PM standards are not sufficiently protective of public health. Since the last review in 2004, sound new studies indicate adverse effects at lower short- and long-term PM levels as documented in the EPA’s own PM Integrated Science Assessment (4). Based on this available evidence, we support the most protective long-term (annual average) standard at 11 μg/m<sup>3</sup> and the short-term (24-h average) PM<sub>2.5</sub> standard at 25 μg/m<sup>3</sup>.

The EPA is under a court-ordered deadline to finalize revised PM standards by December 15, 2012. Every delay in implementation of these PM standards results in potentially long-lasting and severe health effects from what is undoubtedly the largest air quality threat to human health in the United States. We therefore strongly urge the EPA to set a health-protective National Ambient Air Quality Standard for PM<sub>2.5</sub> of 11 μg/m<sup>3</sup> on an annual basis, and 25 μg/m<sup>3</sup> on a 24-hour basis.

**Author disclosures** are available with the text of this article at [www.atsjournals.org](http://www.atsjournals.org).

GEORGE D. THURSTON, SC.D.  
*NYU School of Medicine  
New York, New York*

JOHN R. BALMES, M.D.  
*UCSF School of Medicine  
San Francisco, California  
and  
UC Berkeley School of Public Health  
Berkeley, California*

ON BEHALF OF THE ENVIRONMENTAL HEALTH POLICY COMMITTEE  
OF THE AMERICAN THORACIC SOCIETY

### References

1. Ozkaynak H, Thurston GD. Associations between 1980 US mortality rates and alternative measures of airborne particle concentration. *Risk Anal* 1987;7:449–460.
2. Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, *et al.* An association between air pollution and mortality in six US cities. *N Engl J Med* 1993;329:1753–1759.
3. Pope CA III, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, Thurston GD. Lung cancer, cardiopulmonary mortality and long-term exposure to fine particulate air pollution. *JAMA* 2002;287:1132–1141.
4. U.S. Environmental Protection Agency. Integrated Science Assessment for Particulate Matter (Final Report). Washington, DC: U.S. Environmental Protection Agency, 2009. EPA/600/R-08/139F, Washington, DC. Available from: <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
5. Fann N, Lamson AD, Anenberg SC, Wesson K, Risley D, Hubbell BJ. Estimating the national public health burden associated with exposure to ambient PM<sub>2.5</sub> and ozone. *Risk Anal* 2012;32:81–95.

6. Laden F, Schwartz J, Speizer FE, Dockery DW. Reduction in fine particulate air pollution and mortality: extended follow-up of the Harvard Six Cities Study. *Am J Respir Crit Care Med* 2006;173:667–672.
7. Pope CA III, Ezzati M, Dockery DW. Fine-particulate air pollution and life expectancy in the United States. *N Engl J Med* 2009;360:376–386.
8. U.S. EPA. The benefits and costs of the Clean Air Act from 1990 to 2020. Research Triangle Park, NC: Office of Air and Radiation; 2011.
9. Avol EL, Gauderman WJ, Tan SM, London SJ, Peters JM. Respiratory effects of relocating to areas of differing air pollution levels. *Am J Respir Crit Care Med* 2001;164:2067–2072.

Copyright © 2012 by the American Thoracic Society  
DOI: 10.1165/rcmb.2012-0414ED